Following your reply, please could you provide the information requested in sections 2, 3 and 5 regardless of indication.

1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?

2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)

3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?

4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?

5. Of these patients how many are currently being treated with each of the following TKIs?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)
· Other (i.e. not on a TKI)

Download response Chronic Myeloid Leukaemia (CML) 2015 (follow up) 230516